EUVIMEDEUVIMED entdecken
Crossref

Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment

Dana Jung iD, Seo-Gyeong Jo, Eun-Yeung Gong, Ji-Hoon Kim, Kyungsoo Ha, Gabbine Wee, Seok Jae Huh, Young-Hee Jeoung, Seok-Ho Kim iD

Genes & Genomics · 2026-04 · 48 (4) · 523-532

DOI: 10.1007/s13258-025-01733-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes & Genomics, online erschienen am 02.02.2026. Verfasst von Dana Jung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Killer Cells, Natural, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Research Council of Science & Technology, National Research Foundation of Korea, national institute of food and drug safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Adoptive cell therapies employing chimeric antigen receptors (CARs) have achieved remarkable success in hematologic malignancies, yet their efficacy in solid tumors remains limited due to the immunosuppressive tumor microenvironment (TME), which restricts immune cell infiltration and persistence. While CAR-NK cells provide potent cytotoxicity with a favorable safety profile, their tumor penetration is often suboptimal. In contrast, macrophages possess intrinsic tumor-homing and tissue-remodeling abilities that could help overcome these barriers. OBJECTIVE: This study aimed to develop a combinatorial innate-cell immunotherapy integrating nanobody-based mesothelin (MSLN)-targeting CAR-macrophages (CAR-Ms) with CAR-NK cells to remodel the TME and enhance antitumor immunity in pancreatic cancer. METHODS: Using a validated D3 nanobody CAR construct, CAR-Ms were generated from PMA-differentiated THP-1 monocytes and characterized for CAR expression, M1/M2 polarization, migration, phagocytosis, and cytokine secretion. CAR-NK cell migration and cytotoxicity were evaluated using conditioned media (CM) from CAR-M/tumor co-cultures. Synergistic antitumor activity was assessed in an orthotopic MSLN⁺ pancreatic ductal adenocarcinoma (PDAC) model. RESULTS: D3-CAR-Ms exhibited robust CAR expression (> 90%) and sustained an M1-like phenotype (CD86⁺HLA-DR⁺CD204⁻) even after tumor engagement. Functionally, they displayed enhanced migration and infiltration into MSLN⁺ PANC-1 spheroids, along with increased phagocytic and tumoricidal activity. Upon antigen engagement, CAR-Ms secreted high levels of CXCL9, which promoted CAR-NK chemotaxis, degranulation, and cytotoxicity. Sequential administration of CAR-Ms and CAR-NK cells in vivo led to marked tumor regression and durable responses without systemic toxicity. CONCLUSION: Combinatorial nanobody-based CAR-M and CAR-NK therapy reprograms the TME and establishes a CXCL9-driven feed-forward loop between macrophages and NK cells, leading to synergistic innate immune activation and potent tumor control. This strategy provides a mechanistically grounded and translationally feasible framework for next-generation CAR-based immunotherapies targeting MSLN-expressing solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsKiller Cells, NaturalReceptors, Chimeric AntigenImmunotherapy, AdoptiveMacrophagesCarcinoma, Pancreatic DuctalHumansAnimalsMesothelinMiceTumor MicroenvironmentCell Line, TumorGPI-Linked Proteins

Stichwörter der Autor:innen

CAR-NKCAR-macrophageCombinatorial immunotherapyMesothelinPancreatic cancerTumor microenvironment

Substanzen

MesothelinReceptors, Chimeric AntigenMSLN protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Department of Health Science, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea.
  • Department of Medicinal Biotechnology, College of Health Science, Dong-A University, Busan, 49315, Republic of Korea.
  • Osong Medical Innovation Foundation 123, Osongsaengmyeong-Ro, Osong-Eup, Heungdeok-Gu, Cheonju-Si, Chungbuk, 28160, Republic of Korea.
  • Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIHUB), Daegu, 41061, Republic of Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea. doctorhsj@dau.ac.kr.
  • Department of Medicinal Biotechnology, College of Health Science, Dong-A University, Busan, 49315, Republic of Korea. yhjeong2024@dau.ac.kr.

ORCID-Profile: Dana Jung, Seok-Ho Kim

Förderung

  • National Research Council of Science & Technology
  • National Research Foundation of Korea
  • national institute of food and drug safety

Zitieren

APA

Jung, D., Jo, S. G., Gong, E. Y., Kim, J. H., Ha, K., Wee, G., Huh, S. J., Jeoung, Y. H., & Kim, S. H. (2026). Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment. Genes & Genomics, 48(4), 523-532. https://doi.org/10.1007/s13258-025-01733-9

Vancouver

Jung D, Jo SG, Gong EY, Kim JH, Ha K, Wee G, et al. Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment. Genes & Genomics. 2026;48(4):523-532. doi:10.1007/s13258-025-01733-9

BibTeX
@article{Jung2026,
  author = {Jung, Dana and Jo, Seo-Gyeong and Gong, Eun-Yeung and Kim, Ji-Hoon and Ha, Kyungsoo and Wee, Gabbine and Huh, Seok Jae and Jeoung, Young-Hee and Kim, Seok-Ho},
  title = {Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment},
  journal = {Genes & Genomics},
  year = {2026},
  volume = {48},
  number = {4},
  pages = {523--532},
  doi = {10.1007/s13258-025-01733-9}
}
Kostenlos starten →